

-- 37. A vaccine comprising the EHV mutant of claim 32, and a pharmaceutically acceptable carrier or diluent. --

-- 38. A vaccine comprising the EHV mutant of claim 33 and a pharmaceutically acceptable carrier or diluent. --

-- 39. The EHV mutant of claim 21, wherein said deletion is of the HindIII-ClaI fragment. --

-- 40. The nucleic acid molecule of claim 22, wherein said deletion is of the HindIII-ClaI fragment. --

-- 41. A vaccine comprising the EHV mutant of claim 21 and a pharmaceutically acceptable carrier or diluent. --

-- 42. A vaccine comprising the EHV mutant of claim 39 and a pharmaceutically acceptable carrier or diluent. --

-- 43. A vaccine comprising an attenuated equine herpesvirus (EHV) mutant, wherein one or more deletions are introduced into the endogenous promoter region of the Immediate Early gene, and a pharmaceutically acceptable carrier or diluent. --

REMARKS

Claims 1 - 15 are canceled and claims 16 - 43 are added.


Claims 16 - 43 are presented for examination.

New claims 16 - 43 have been added to adapt the claim language to conventional U.S. patent practice and to claim preferred embodiments, and not for purposes of patentability.

It is believed that claims 16 - 43 recite a patentable improvement in the art. Favorable action is solicited. In the

event any fees are required with this paper, please charge our
Deposit Account No. 02-2334.

Respectfully submitted,



Michael G. Sullivan
Attorney for Applicants
Registration No. 35,377

Attorney Docket NO. I/98404 US

Akzo Nobel Patent Department
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850-4373
Tel: (301) 948-7400
Fax: (301) 948-9751

MGS:jlc

11SONDERMEIJER-PRELIMINARY

EXPRESS MAIL EL400659451US

-9-